Jonathan A. Downar - US grants
Affiliations: | University of Toronto, Toronto, ON, Canada |
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the NIH Research Portfolio Online Reporting Tools and the NSF Award Database.The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please sign in and mark grants as correct or incorrect matches.
High-probability grants
According to our matching algorithm, Jonathan A. Downar is the likely recipient of the following grants.Years | Recipients | Code | Title / Keywords | Matching score |
---|---|---|---|---|
2017 — 2018 | Downar, Jonathan Alexander Stewart Woodside, D Blake |
R61Activity Code Description: As part of a bi-phasic approach to funding exploratory and/or developmental research, the R61 provides support for the first phase of the award. This activity code is used in lieu of the R21 activity code when larger budgets and/or project periods are required to establish feasibility for the project. |
@ University Health Network PROJECT SUMMARY This project investigates the utility of dorsomedial prefrontal cortex(DMFPC) repetitive transcranial magnetic stimulation (rTMS) in bingeing and purging in chronic, treatment- resistant bulimia nervosa(BN), and anorexia nervosa, binge-purging subtype(ANBN). rTMS uses powerful, focused magnetic field pulses to change activity in target brain regions. Published pilot work shows 57% of those treated with DMPFC rTMS for bingeing and purging experience both a >50% reduction in both bingeing and purging, and a wide variety of improvements in other domains, including mood, anxiety, and affective regulation. Response in terms of reduced bingeing and purging does not appear to be correlated to other comorbidity. Response is heavily correlated to pre-treatment fronto- striatal connectivity as measured by functional magnetic resonance imaging(frmi), where responders have a consistent pattern of poor connectivity initially compared to non- responders, which pattern normalizes over the course of treatment The aims of the proposed R61/33 phased trial are to 1) confirm target engagement and determine an optimal dosing paradigm(R61 phase); and 2) ensure that the results are not due to a placebo effect, determine the clinical effectiveness and duration of effect, and begin to examine the potential use of pre-treatment fMRI as a biomarker of treatment suitability(R33 phase). Subjects in the R61 arm will undergo 30 bilateral rTMS treatments accompanied by a suite of imaging, clinical, psychometric, and psychological test assessments, in two dosage regimens and a sham arm. In the R33 phase, the optimal dosing regimen will be used with a novel active/sham coil to administer 20 rTMS treatments in a triple blind design. Subjects will again be assessed as in the R61 phase. If successful, the study will provide evidence for the future development of rTMS as a novel, effective treatment for refractory BN and ANBP, and further information as to the neural mechanisms both of the illnesses and the mechanism of response to rTMS. |
0.948 |
2019 | Downar, Jonathan Alexander Stewart Gunning, Faith M Liston, Conor M |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Efficacy of Biomarker-Guided Rtms For Treatment Resistant Depression @ Weill Medical Coll of Cornell Univ Major depressive disorder (MDD) is a leading cause of global disability, and approximately 30% of MDD patients are resistant to conventional antidepressant pharmacotherapy. Repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (DLPFC) is an FDA-cleared intervention with proven efficacy in treatment-resistant depression, but only 30?40% of these patients achieve remission after a single course. Other studies have shown that rTMS targeting the dorsomedial PFC (DMPFC) is comparably effective, but biomarkers for informing target site selection and predicting differential treatment response are not currently available. Diagnostic heterogeneity has been a major obstacle to biomarker discovery efforts. Recently, we developed and validated an approach to diagnosing four novel MDD subtypes or ?biotypes? defined by distinct resting state functional connectivity (RSFC) patterns in Valence System circuits and predicting differing antidepressant responses at the individual level to rTMS targeting the DMPFC. This confirmatory efficacy trial will test a novel, biotype-guided treatment selection strategy motivated by the hypothesis that an individual patient's likelihood of responding to left DLFPC vs. DMPFC rTMS is determined in part by individual differences in 1) the degree to which their symptoms are driven by dysfunction in specific downstream amygdala, striatal, and salience network targets comprising aspects of Valence Systems; and 2) the degree to which dysfunction in those targets can be modulated by stimulating the left DLPFC or DMPFC. Subjects (N=405) will be randomized to receive a) biotype-guided 10 Hz rTMS targeting the DMPFC or left DLPFC; b) to a disconfirmation arm receiving rTMS targeting the opposite site; and c) to a third arm receiving FDA-cleared, standard-of-care 10 HZ rTMS targeting the left DLFPC, regardless of biotype. All patients will be tested before and after treatment on a battery of fMRI, behavioral, and clinical assessments, grounded in RDoC-informed measures of emotion regulation and effort valuation, which will enable us to validate downstream brain circuit treatment targets and test for target engagement, in conjunction with state-of-the-art, anatomically realistic electric field modeling and fiber tractography. The primary goal is to confirm the efficacy of a novel RSFC biomarker-guided approach to differential treatment selection in treatment resistant depression, with the potential for significantly enhanced efficacy compared to the current standard-of-care. |
0.921 |